澜起科技股份有限公司 2025 年度业绩快报公告 证券代码：688008 证券简称：澜起科技 公告编号：2026-013 二、经营业绩和财务状况情况说明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以澜起科技股份有限公司（以下简称"公司"）2025年年度报告为 准，提请投资者注意投资风险。 | | | | 单位：人民币万元，万股 | | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期 | 增减变动幅度 （%） | | 营业总收入 | 545,631.68 | 363,891.11 | 49.94 | | 营业利润 | 232,177.71 | 141,289.32 | 64.33 | | 利润总额 | 232,056.81 | 141,261.79 | 64.27 | | 归属于母公司所有者的净利润 | 223,557.00 | 141,177.89 | 58.35 | | 归属于母公司所有者的扣除非 ...

| 证券代码：688223 | 证券简称：晶科能源 | 公告编号：2026-011 | | --- | --- | --- | | 债券代码：118034 | 债券简称：晶能转债 | | 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 晶科能源股份有限公司 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以晶科能源股份有限公司（以下简称"公司"）2025 年年度报告 为准，敬请投资者注意投资风险。 | | | | 单位：人民币万元 | | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期 | 增减变动幅 度（%） | | 营业总收入 | 6,549,191.74 | 9,247,132.72 | -29.18 | | 营业利润 | -910,556.34 | 79,296.42 | -1,248.29 | | 利润总额 | -910,862.71 | -7,705.66 | 不适用 | | 归属于母公司所有者的净利润 | ...

Financial Performance - Total revenue for 2025 was RMB 26,168.39 million, a decrease of 57.92% compared to RMB 62,184.37 million in the previous year[4] - Net profit attributable to the parent company was a loss of RMB 47,190.44 million, worsening from a loss of RMB 6,326.40 million in the previous year[4] - Basic earnings per share were -RMB 4.99, compared to -RMB 0.65 in the previous year[4] - The weighted average return on net assets decreased by 79.62 percentage points to -86.80% from -7.18%[4] Asset and Equity Changes - Total assets increased by 3.68% to RMB 211,740.13 million from RMB 204,223.59 million at the beginning of the period[4] - Equity attributable to the parent company decreased by 62.93% to RMB 30,410.68 million from RMB 82,030.89 million at the beginning of the period[4] - The decline in equity and net asset per share was primarily due to significant losses from reduced gross margins and impairment provisions[10] Operational Challenges - The decline in revenue was attributed to longer acceptance cycles for key customer products and increased competition in the lithium battery industry, leading to lower prices[7] - The company conducted a comprehensive impairment test on inventory, resulting in increased asset impairment losses due to new provisions for inventory depreciation[7] Future Strategies - The company plans to improve operational efficiency and enhance cost control to gradually increase gross margins and profitability[8]

Financial Performance - Total revenue for 2025 was RMB 580,247,506.79, a decrease of 5.97% compared to RMB 617,105,267.83 in the previous year[4] - Net profit attributable to shareholders was RMB 50,695,382.00, down 24.10% from RMB 66,792,883.25 year-on-year[4] - The weighted average return on equity decreased to 4.45% from 5.75% in the previous year[4] - Total assets at the end of the reporting period were RMB 2,268,640,596.56, a decrease of 1.48% from RMB 2,302,726,225.34 at the beginning of the period[4] - The net asset per share attributable to shareholders increased to RMB 9.54, up 4.49% from RMB 9.13[4] Business Transition and Product Development - The company completed the transition from an "engineering company" to a "product and technology company" in 2025[8] - The company delivered a total of 13 sets of the new water treatment robot "New Water Island®" and 14 sets of the "Water Radish® AI Intelligent Body" by the end of 2025[7] - The company increased its marketing efforts for the "New Water Island®" product, leading to higher sales expenses[8] - The company faced pressure on profits due to increased financial costs from newly operational wastewater resource projects[8] - The company established an AI Innovation Research Center in collaboration with Wuhan University to focus on cutting-edge AI technology applications in water treatment[8]

Financial Performance - In 2025, the total operating revenue reached RMB 342.94 million, a year-on-year increase of 1.95%[5] - The net profit attributable to shareholders of the parent company was RMB 52.26 million, a decrease of 47.04% compared to the previous year[5] - The net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was RMB 41.37 million, down 42.30% year-on-year[5] - The basic earnings per share decreased by 41.62% to RMB 1.15[3] Assets and Equity - The company's total assets at the end of the reporting period were RMB 1,898.69 million, a decrease of 1.41% from the beginning of the period[3] - The equity attributable to shareholders of the parent company was RMB 1,728.26 million, down 2.08% from the beginning of the period[3] Research and Development - The company increased its R&D investment by 5.14% to maintain product advancement and accelerate technology iteration[6] Expenses and Costs - Management expenses increased by 68% due to the new park's operational and amortization costs[6] - The decline in the factory price of the disposable breast biopsy needle due to centralized procurement led to a decrease in gross profit by RMB 22.02 million[7] Financial Income - Financial income decreased by 63% due to a decline in investment yield[6]

Financial Performance - Total revenue for 2025 reached ¥1,368,119.42 million, a 31.07% increase compared to ¥1,043,802.05 million in the previous year[4] - Net profit attributable to shareholders of the parent company was -¥98,891.53 million, an increase in loss of ¥20,412.99 million from -¥78,478.54 million year-on-year[7] - The basic earnings per share for the period was -¥0.74, compared to -¥0.59 in the previous year[4] - The weighted average return on equity was -21.38%, a decrease of 7.07 percentage points from -14.31%[4] Assets and Equity - Total assets at the end of the reporting period were ¥3,454,636.38 million, an 18.29% increase from ¥2,920,500.87 million at the beginning of the period[7] - Shareholders' equity attributable to the parent company decreased by 19% to ¥414,010.78 million from ¥511,119.51 million[4] Operational Challenges - The company experienced a decrease in gross profit margin due to intensified competition in the offshore wind market and rising component prices[7] - The company faced delays in the construction progress of some offshore wind projects, impacting the timely conversion of sales orders into revenue[7] Cost Management - The company controlled expenses effectively, resulting in a 4 percentage point decrease in the expense ratio compared to the previous year[7] Revenue Drivers - The increase in revenue was primarily driven by a significant rise in new orders for wind turbine products in 2024[8]

中科寒武纪科技股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载 2025 年度（以下简称"报告期"或"本期"）主要财务数据为初步核算 数据，未经会计师事务所审计，具体数据以中科寒武纪科技股份有限公司（以下简称"公 司"）《2025 年年度报告》为准，敬请投资者注意投资风险。 证券代码：688256 证券简称：寒武纪 公告编号：2026-002 一、2025年度主要财务数据和指标 项目 本报告期 上年同期 增减变动幅 度（％） 营业总收入 6,497,196,198.68 1,174,464,377.35 453.21 营业利润 2,061,390,034.78 -455,745,242.97 不适用 利润总额 2,059,381,570.35 -455,769,055.47 不适用 归属于母公司所有者的净利 润 2,059,228,538.67 -452,338,791.01 不适用 归属于母公司所有者的扣除 非经常性损益的净利润 1,769,934,157.68 -86 ...

Financial Performance - Total revenue for 2025 was RMB 1,161,293,570.09, a decrease of 55.19% compared to RMB 2,591,394,411.64 in the previous year[5] - The net loss attributable to shareholders was RMB 480,839,271.14, an improvement of 13.90% from a loss of RMB 558,435,934.01 in the previous year[5] - Total assets at the end of the reporting period were RMB 2,571,991,745.51, down 20.24% from RMB 3,224,646,284.11 year-on-year[5] - The equity attributable to shareholders decreased by 29.65% to RMB 1,130,617,980.96 from RMB 1,607,035,005.55[5] Business Strategy - The company is focusing on enhancing sustainable development capabilities and accelerating overseas business expansion in the photovoltaic film sector[9] - The company is exploring a dual-main business development model, with new PDCLC smart dimming film products gaining recognition from downstream customers and several main engine manufacturers[9] Market Challenges - The decline in revenue was primarily due to intense price competition in the photovoltaic industry and reduced sales volume, leading to low gross margins[10] - The company has incurred asset impairment losses due to low capacity utilization rates and the recoverable amounts of certain assets being lower than their book values[10] - Ongoing R&D and market investments in new business areas have negatively impacted profits[10] Financial Reporting - The financial data presented is preliminary and unaudited, with potential discrepancies in the final annual report[11]

Financial Performance - Total revenue for 2025 reached CNY 3.55 billion, an increase of 16.81% year-on-year[4] - Net profit attributable to shareholders of the parent company was CNY -0.09 billion, a decline of 104.61% compared to the previous year[4] - Basic earnings per share were CNY -0.03, a decrease of 103.80% year-on-year[4] - The weighted average return on net assets was -0.21%, down 4.67 percentage points from the previous year[4] - Shareholders' equity attributable to the parent company decreased by 2.17% to CNY 4.49 billion[8] Assets and Investments - The company's total assets at the end of the reporting period were CNY 8.93 billion, reflecting a year-on-year growth of 6.85%[8] - The company invested significantly in advanced production capacity, resulting in a fixed asset scale increase of approximately CNY 3.5 billion compared to 2022[10] Research and Development - R&D expenses for the reporting period amounted to approximately CNY 270 million, an increase of about CNY 150 million from 2022[12] Workforce and Labor Costs - The company increased its workforce by approximately 1,700 employees to support new operational bases, leading to a rise in labor costs[11] Strategic Goals - The company aims to enhance its long-term development through strategic investments in capacity, talent, and technology[9]

Financial Performance - The total operating revenue for 2025 reached RMB 452.49 million, an increase of 39.10% compared to RMB 325.29 million in the previous year[3] - The net profit attributable to the parent company was RMB 18.89 million, an increase of RMB 40.59 million from a net loss of RMB 21.70 million in the previous year[6] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 8.21 million, an increase of RMB 46.30 million from a net loss of RMB 38.09 million in the previous year[6] - The earnings per share for the period was RMB 0.25, compared to a loss of RMB 0.29 in the previous year[3] - The weighted average return on equity increased to 2.48%, up by 5.27 percentage points from -2.79% in the previous year[3] Assets and Equity - The total assets at the end of 2025 were RMB 1,407.71 million, a year-on-year increase of 1.99%[6] - The equity attributable to the parent company was RMB 796.47 million, an increase of 5.77% compared to RMB 753.01 million at the beginning of the period[4] Operational Strategies - The company focused on optimizing product structure and increased sales of traditional Chinese medicine intelligent products and pharmaceutical information products, contributing to profit growth[7] - The company implemented cost reduction and efficiency enhancement measures, which improved cash collection and management capabilities, positively impacting profitability[7] Reporting Accuracy - There are no significant uncertainties affecting the accuracy of the performance report, and the data is preliminary and subject to final audit[10]